.png){kind=small}
%20(1).png){kind=small}
%20(2).png){kind=small}
Animal studies are expensive, time-consuming, and often don't predict human outcomes as well as you'd think. For many medical devices, there's a better path for your medical device program.
Summary
For many medical devices, animal studies are not required and often add cost, time, and limited insight compared with a rigorous bench-forward approach. FDA’s framework allows reasonable assurance of safety to be established through bench testing, biocompatibility (ISO 10993), risk management (ISO 14971), and, when appropriate, Early Feasibility Studies with robust clinical safeguards. Animal studies are warranted for novel materials, complex tissue interactions, high-risk indications, or when FDA explicitly expects them—but are unnecessary when questions are primarily mechanical, materials are well characterized, or suitable models don’t exist. Disciplined and planned FDA engagement and a well-justified strategy can reach first-in-human faster with more relevant data.
The Assumption Nobody Questions
When most medtech teams start planning their preclinical strategy, animal studies get penciled in almost automatically. It feels like the responsible thing to do. It feels like what the FDA wants. Often, an animal study is added simply because it seems expected. And for decades, it's been treated as a standard step on the road to first-in-human.
But here's the reality: for medical devices, animal studies are often not required, not particularly informative, and not the best use of your development timeline or budget. At Prime Path, we regularly help clients build preclinical strategies that get to first-in-human faster by questioning whether animal studies are actually the right tool for the job --- and more often than not, the answer is that they aren't.
Medical Devices Aren't Drugs –– The Rules Are Different
A lot of the conventional wisdom around animal studies comes from the pharmaceutical world, where animal testing is deeply embedded in the regulatory framework. Drug developers use animal models to identify toxicity thresholds, calculate safe starting doses, and model how a compound moves through the body. That framework makes sense for drugs --- you're introducing a chemical that interacts with biology in ways that are genuinely hard to predict without a living system.
Medical devices work differently. A knee implant doesn't get metabolized. A catheter doesn't have a dose-response curve. A cardiac monitor doesn't interact with receptors. For most devices, the primary safety questions are mechanical and material in nature --- and those questions can usually be answered at the bench.
The FDA's regulatory framework reflects this. Under 21 CFR Part 812, the IDE regulations don't mandate animal studies. What they require is evidence sufficient to establish reasonable assurance of safety. How you build that evidence package is largely up to you --- and bench testing, computational modeling, and biocompatibility data can often get you there without a single animal.
The Translation Problem Is Real
Even when animal studies are conducted, the data doesn't always tell you what you think it does. The biological differences between species --- anatomy, tissue mechanics, healing response, immune reaction --- mean that a device that performs well in a porcine model or a sheep may behave very differently in a human. And a device that causes an adverse response in an animal may be perfectly safe in a person.
This translation gap isn't a fringe concern. It's well documented across the medical literature and increasingly acknowledged by the FDA itself. The agency's push toward more flexible preclinical frameworks, including the Early Feasibility Study pathway, reflects a recognition that animal data isn't always the most meaningful signal --- and that getting to human data sooner, under controlled conditions with careful monitoring, can actually produce better safety information.
The uncomfortable truth is that some teams run animal studies, generate imperfect data, spend months interpreting it, and then reach FIH having learned less than they would have from a tightly designed bench testing program and a well-monitored first-in-human study.
When Animal Studies Make Sense –– and When They Don't
To be clear, we're not arguing that animal studies are never appropriate. There are situations where they add genuine value and where FDA will expect them. The point is that the decision should be deliberate and evidence-based, not automatic.
A well-designed animal study is likely worth pursuing when:
- Your device involves a novel material with no prior clinical use history and limited biocompatibility data
- The device interacts with tissue in ways that bench testing can't adequately simulate --- chronic inflammatory response, for example, or tissue ingrowth around an implant
- You're developing a device for a high-risk indication where failure modes are severe and bench surrogates are limited
- FDA has specifically signaled in pre-submission feedback that animal data is expected for your device category
Animal studies are often not the right path when:
- Your device is made from well-characterized materials with an established biocompatibility record
- The primary safety questions are mechanical --- fatigue, wear, dimensional tolerance --- and can be answered with validated bench tests
- Suitable animal models don't exist or don't provide anatomically relevant data for your specific device and indication
- The time and cost of a well-designed animal study would meaningfully delay your path to clinical data that will be more informative anyway
What a Bench-Forward Strategy Actually Looks Like
Skipping animal studies doesn't mean skipping rigor. It means redirecting that rigor toward evidence that more directly answers the FDA's core question: is there reasonable assurance that this device is safe for human use?
A bench-forward preclinical strategy typically includes comprehensive mechanical and performance testing with pre-specified acceptance criteria, a thorough biocompatibility evaluation under ISO 10993-1 using a risk-based approach that leans heavily on materials characterization and existing data, a detailed FMEA and risk analysis under ISO 14971, computational modeling where applicable, and a clinical protocol designed with enhanced safety monitoring to account for any residual uncertainty in the preclinical package. Complement this with human factors engineering and formative usability testing for your medical device to identify and mitigate use-related risks before FIH.
The last point matters. If you're making the case to FDA that bench data is sufficient, your clinical protocol needs to reflect that you've thought carefully about what you don't yet know. Robust stopping rules, a conservative subject enrollment ramp, and a detailed safety monitoring plan signal to FDA that you understand the limits of your preclinical package and have built protections around them.
Timing FDA Engagement: Lead with Data, Not Questions
The timing and structure of FDA engagement matter more than most teams realize. While the Agency positions itself as accessible and collaborative, the reality is that feedback can vary widely depending on the reviewers involved, and it often skews conservative—sometimes extending beyond what is practically necessary.
For that reason, engaging too early, before you have a well-developed data package and a clearly articulated rationale, can create unnecessary headwinds. Early, underdeveloped discussions tend to invite broad hypothetical concerns that may not ultimately be relevant but can shape expectations and increase burden downstream.
A more effective approach is to engage once you have a disciplined, evidence-backed position—supported by robust bench data, a clear risk framework, and a well-designed clinical protocol. At that point, the conversation becomes more focused and grounded, allowing you to guide the dialogue rather than react to it.
This is especially important when proposing to forgo animal studies; success depends less on asking permission early and more on presenting a cohesive, well-substantiated case at the right moment.
What Prime Path Does Differently
Most regulatory consultants will default to recommending animal studies because it feels conservative. We take a different approach. We look at your device, your materials, your indication, and your timeline and ask whether animal studies will actually move the needle on your FDA submission --- or whether they'll consume six to twelve months and $200,000 to generate data that doesn't materially change your path to approval.
When animal studies aren't warranted, we help you build the bench-forward preclinical case that holds up under FDA review. When they are warranted, we help you design them to be as efficient and translatable as possible --- so you're not running a study that produces more questions than answers. We also integrate human factors planning so use-related risks don't become late-stage surprises in your clinical program.
Getting to first-in-human faster isn't about cutting corners. It's about being strategic with where you invest your preclinical resources, and having the regulatory expertise to defend that strategy confidently.
Bottom Line
Animal studies have a place in medical device development. But that place isn't automatic, and it isn't every program. For many devices, a well-executed bench testing program and a carefully designed first-in-human study will get you to better data faster, at lower cost, and with less regulatory friction than a mandatory detour through an animal study or animal work that wasn't designed to answer the right questions in the first place.
If you're planning a preclinical strategy and want an honest assessment of whether animal studies belong in it, that's exactly the kind of conversation Prime Path is built for.
Q&A
Question: Does FDA require animal studies for medical devices before first-in-human?
Short answer: No. Under 21 CFR Part 812, FDA does not mandate animal studies; it requires reasonable assurance of safety. For many devices, that assurance can be established with a bench-forward package—validated mechanical/performance testing, biocompatibility per ISO 10993, risk management per ISO 14971, and, where appropriate, computational modeling and an Early Feasibility Study (EFS) protocol with robust safeguards.
Question: When do animal studies make sense—and when do they not?
Short answer: They’re appropriate when your device uses novel materials lacking clinical history, involves tissue responses bench tests can’t simulate (e.g., chronic inflammation or ingrowth), targets high-risk indications with severe failure modes, or FDA explicitly expects them. They’re often unnecessary when materials are well characterized, safety questions are primarily mechanical and answerable at the bench, relevant animal models don’t exist, or the time/cost would delay more informative early human data.
Question: What does a “bench-forward” preclinical strategy include?
Short answer: It centers on comprehensive bench testing with predefined acceptance criteria; a risk-based biocompatibility evaluation under ISO 10993-1 leveraging materials characterization and existing data; risk analysis/FMEA under ISO 14971; computational modeling where applicable; and human factors engineering and formative usability testing. The clinical protocol should add protections—clear stopping rules, conservative enrollment ramp, and detailed safety monitoring—to account for any residual uncertainty.
Question: How do I get FDA on board with skipping animal studies?
Short answer: Engage when you have robust data via a pre-submission to present a clear, evidence-backed rationale: why your device category, materials, and intended use don’t warrant animal testing; how your bench and biocompatibility data address safety; and what clinical safeguards you’ll implement. FDA’s EFS pathway is designed for leaner preclinical packages. Sponsors can successfully engage if they have data and frame the conversation with the FDA, especially when your plan is well reasoned.
.png)
